Satellos Bioscience (MSLE) EBITDA (2025 - 2026)
Satellos Bioscience (MSLE) posted quarterly EBITDA of -$9.7 million for Q1 2026, down 260.17% year-over-year from $6.1 million in Q1 2025, and down 260.17% quarter-over-quarter from $6.1 million in Q1 2025.
Satellos Bioscience (MSLE) EBITDA (2025 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has reported EBITDA for 2 consecutive years, with -$9.7 million the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 133.12 Mn |
| 10 | Satellos Bioscience | 207.06 Mn | 207.06 Mn | - | -11.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.74 Mn |
| Mar 31, 2025 | 6.08 Mn |